We combine deep market expertise with a personalized approach to help you achieve your financial goals.
Our platform is built for speed, scalability compliance, ensuring smooth transactions across every channel. With transparent pricing, seamless integrations, a dedicated support.
Personalized Investment Strategies
We understand that every investor’s goals, risk tolerance, and financial situation are unique we create custom-tailored investment
Diversified Portfolio Management
We understand that every investor’s goals, risk tolerance, and financial situation are unique we create custom-tailored investment
Advanced Risk Management
We understand that every investor’s goals, risk tolerance, and financial situation are unique we create custom-tailored investment
Regular Performance Reporting
We understand that every investor’s goals, risk tolerance, and financial situation are unique we create custom-tailored investment
Everyone knows what Ozempic does at a full pharmaceutical dose. Almost nobody knows what a fraction of that dose does — with a fraction of the side effects. GLP-1 micro-dosing is rewriting the metabolic health conversation. But it's one piece of a larger picture: metabolic dysfunction is an inflammation problem, a mitochondrial problem, and a gut problem. Peptide therapy addresses all three.
Metabolic HealthGLP-1 Micro-DosingBody CompositionMitochondrial Support
88%
Of American adults are metabolically unhealthy by at least one marker — blood sugar, triglycerides, HDL, blood pressure, or waist circumference
70%
Of GLP-1 side effects occur at standard pharmaceutical doses — and drop sharply at micro-doses, opening a metabolic window with far better tolerability
1 in 3
Adults in the US has prediabetes — the majority undiagnosed, sitting in a window where peptide intervention can meaningfully reverse the trajectory
The Core Framework
Metabolic Dysfunction Is an Inflammation Problem — Not a Willpower Problem
Reframing weight gain and metabolic decline from behavioral to biological changes the entire treatment approach.
The standard narrative around weight gain and metabolic decline is behavioral — eat less, move more, try harder. This framework fails most people not because they lack willpower, but because it misidentifies the root cause. Metabolic dysfunction is primarily driven by chronic inflammation, mitochondrial failure, gut permeability, and hormonal dysregulation — all biological processes that no amount of caloric restriction can directly fix.
Chronic inflammation impairs insulin receptor sensitivity, making cells resistant to glucose uptake regardless of dietary intake. Mitochondrial dysfunction reduces the efficiency with which cells convert fuel to energy. Gut permeability drives the systemic inflammation that makes both worse. And declining GH after age 35 shifts body composition toward fat accumulation independently of diet.
Peptide therapy addresses these upstream biological drivers. GLP-1 receptor agonists at micro-doses reduce appetite signaling and improve insulin sensitivity without the nausea of pharmaceutical doses. AOD 9604 directly promotes lipolysis. BPC-157 heals the gut permeability driving metabolic inflammation. MOTS-c and Methylene Blue target mitochondrial function. The goal is restoring metabolic biology — not overriding it with extreme doses.
The Micro-Dosing Distinction
Standard pharmaceutical GLP-1 doses (1–2.4 mg/week semaglutide) were designed for maximal weight loss in clinical trials. Micro-dosing uses 5–20% of that dose — enough to meaningfully improve insulin sensitivity and reduce inflammatory appetite signaling without the nausea, vomiting, and rapid muscle loss that characterize high-dose protocols. It's not a lesser version of Ozempic — it's a different clinical application entirely.
GLP-1 Micro-Dosing Explained
Standard Dose vs Micro-Dose — What Changes and Why
The dose-response curve for GLP-1 is non-linear. Most of the metabolic benefit occurs at lower doses. Most of the side effects occur at higher ones.
Standard Pharmaceutical Dose
Ozempic / Wegovy Protocol
Typical dose (semaglutide)0.5–2.4 mg/week
Primary goalMaximal weight loss
Nausea / GI side effects40–70% of patients
Muscle loss riskSignificant — 25–40% of lost weight is lean mass
Cost$900–$1,400+/month (brand)
Best suited forClinically significant obesity with physician oversight
GLP-1 Micro-Dose
Peptide Therapy Approach
Typical dose (semaglutide)0.05–0.25 mg/week
Primary goalMetabolic health + gradual body composition
Nausea / GI side effectsLow — most patients tolerate well
Muscle loss riskMinimal — gradual pace preserves lean mass with protein + resistance training
CostSignificantly lower via compounding
Best suited forMetabolic health, insulin resistance, moderate weight loss, longevity
Why the Risk Curve Is Non-Linear
GLP-1 receptors in the brain's appetite centers are highly sensitive — meaningful signal reduction occurs at low doses. GI side effects result from overwhelming gut GLP-1 receptors, which requires much higher doses. The therapeutic window for metabolic benefit without significant GI side effects is real — and it's why compounded micro-dose protocols are gaining significant clinical traction among functional medicine practitioners.
The Metabolic Dysfunction Cascade — Where Peptides Intervene
Metabolic dysfunction follows a biological cascade — gut permeability drives inflammation, which drives insulin resistance, which drives mitochondrial failure, which drives weight gain. Effective peptide therapy targets multiple stages simultaneously.
Condition Guides in This Category
Metabolic Conditions We Cover
Research-backed guides for each condition — with full protocols, lab guidance, and provider conversation scripts.
Metabolic · Priority #9
Weight Loss & Metabolic Health
Anchor: GLP-1 Micro-Dosed
The most anticipated guide in this category. Covers the GLP-1 micro-dosing explainer, the non-linear side effect risk curve, the anti-inflammatory weight loss framing, AOD 9604 for targeted lipolysis, and how to build a protocol that loses fat while preserving lean mass. Includes the metabolic labs to order before starting and a realistic 6-month timeline.
PCOS is increasingly understood as a downstream consequence of insulin resistance, gut inflammation, and immune dysregulation — not simply an ovarian condition. Covers the labs-first framework, GLP-1 micro-dose for insulin resistance, the mitochondrial stack for reversing insulin sensitivity, and gut peptides for the inflammatory root.
Type 2 diabetes and pre-diabetes are the downstream outcomes of the metabolic cascade — insulin resistance compounded by mitochondrial dysfunction. Covers GLP-1 micro-dosing alongside existing diabetes medications, the MOTS-c + Methylene Blue mitochondrial reversal protocol, and the gut healing dimension that most diabetes care ignores.
Cardiovascular disease is an inflammatory condition driven by the same metabolic cascade. BPC-157 reduces vascular inflammation. NAD+ supports mitochondrial function in cardiac muscle. GLP-1 receptors in the heart explain the cardiovascular protective effects documented in major GLP-1 trials — benefits that occur independently of weight loss.
Overlaps with other categories:Hormonal Health — declining GH drives body composition toward fat accumulation independently of diet. Gut Health & Immunity — gut permeability is the upstream driver of the metabolic inflammation cascade. Addressing these in parallel produces significantly better metabolic outcomes.
The Peptide Stack
Peptides Used in Metabolic Health
Five peptides targeting the cascade at different points — from gut repair through insulin sensitivity to direct lipolysis and mitochondrial restoration.
GLP-1 (Micro-Dosed)
★ Insulin Sensitivity Anchor
Semaglutide or tirzepatide at 5–20% of standard pharmaceutical dose. Meaningfully improves insulin sensitivity, reduces inflammatory appetite signaling, and provides cardiovascular protection — with dramatically lower side effects. Requires physician prescription and monitoring.
Profile
AOD 9604
Targeted Lipolysis
The C-terminal fragment of human GH — specifically the fat-metabolizing portion, without the anabolic effects of full GH. Directly stimulates lipolysis and inhibits lipogenesis. No blood sugar effects. Frequently stacked with GLP-1 micro-dose for additive fat loss without redundancy.
Full Profile
BPC-157
Gut-Metabolic Root
Addresses the gut permeability driving the metabolic inflammation cascade. Repairs tight junctions, reduces LPS-driven systemic inflammation, and supports the gut microbiome diversity that metabolic health depends on. The first intervention in most metabolic protocols — because the cascade starts in the gut.
Full Profile
MOTS-c
Mitochondrial Metabolism
A mitochondria-derived peptide encoded in mitochondrial DNA. Regulates metabolic homeostasis, activates AMPK (the cellular energy sensor), and directly improves insulin sensitivity through mitochondrial-nuclear signaling. Levels decline with age — a direct target for age-related metabolic decline.
Profile
CJC-1295 + Ipamorelin
GH & Body Composition
Declining GH after 35 shifts body composition toward fat accumulation regardless of diet. Restoring GH axis function directly addresses the hormonal contribution to metabolic decline. Most valuable when low IGF-1 is documented on labs — the hormonal layer on top of the inflammatory foundation.
Profiles
"Micro-dosing GLP-1 isn't a lesser version of Ozempic. It's a different clinical tool — optimizing metabolic health rather than maximizing weight loss at any cost. The dose determines the indication."
Where to Start
The Metabolic Protocol — In Order
The cascade runs gut → inflammation → insulin resistance → mitochondria. The protocol runs in the same direction.
Step 1 — Labs First
Essential metabolic baseline before any intervention. Fasting insulin (most important — reveals insulin resistance before glucose rises), fasting glucose + HbA1c, hsCRP (inflammatory baseline), IGF-1, lipid panel. Fasting insulin above 10 μIU/mL signals significant insulin resistance even with normal blood sugar. This baseline determines which peptides are most needed.
Step 2 — Gut Foundation
Oral BPC-157 first — the upstream driver of metabolic inflammation. 250–500 mcg/day on empty stomach. Repairing gut permeability reduces the LPS-driven systemic inflammation impairing insulin receptor sensitivity. For many people, gut healing alone produces measurable improvements in energy, inflammatory markers, and food cravings within 4–6 weeks.
Step 3 — GLP-1 Micro-Dose
Under physician guidance — after gut foundation is established. Start at the lowest available dose (0.05–0.1 mg/week semaglutide equivalent) and titrate slowly. The goal is meaningful insulin sensitivity improvement without GI side effects. The gut healing from Step 2 often reduces GLP-1 side effects — a genuine synergy between the two interventions.
Step 4 — Add AOD 9604
Targeted lipolysis layer for body composition goals. AOD 9604 at 200–300 mcg/day (morning, fasted) directly promotes fat oxidation without affecting blood sugar or IGF-1. Complements GLP-1's insulin sensitivity effect — different mechanisms, additive results. Most effective after 6–8 weeks of the gut and GLP-1 foundation.
Step 5 — Mito Layer
MOTS-c + Methylene Blue for metabolic efficiency. When insulin resistance persists despite Steps 1–4, or when fatigue and poor energy conversion are prominent, the mitochondrial layer becomes essential. MOTS-c addresses AMPK signaling linking mitochondrial function to insulin sensitivity. Methylene Blue directly supports electron transport chain efficiency — addressing the cellular energy dimension that diet and GLP-1 alone can't fully correct.
Free Resource
Get the Metabolic Health Peptide Primer
A free starter guide covering the metabolic labs to order, how to read your fasting insulin, the GLP-1 micro-dosing basics, and the cascade framework — before your first provider conversation.
No spam. Unsubscribe anytime. We'll notify you when Weight Loss, PCOS, and Diabetes guides publish.
Protocol Guides
Go Deeper — The Full Protocol Guides
Complete Protocol Guide
AOD 9604 Protocol Guide
AOD 9604 dosing and cycling, how to stack with GLP-1 micro-dose, lab monitoring, lipolysis mechanism explained, and a provider conversation script for your metabolic health appointment.
The full five-step metabolic cascade protocol — BPC-157 gut foundation, GLP-1 micro-dose introduction, AOD 9604 timing, mitochondrial layer, and the lab monitoring schedule from baseline through 6 months.
Download the free Metabolic Primer — fasting insulin interpretation, the cascade framework, GLP-1 micro-dosing basics, and the labs to order before your first provider conversation.
